Related Experiment Video
Updated: May 9, 2026
An Ex Vivo Model of Ovarian Cancer Peritoneal Metastasis Using Human Omentum
Published on: January 26, 2024
Association of myeloperoxidase with ovarian cancer
Dan Cacsire Castillo-Tong1, Dietmar Pils, Georg Heinze
1Department of Obstetrics and Gynaecology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Abstract:
Myeloperoxidase (MPO) is an oxidant generating enzyme normally restricted to myeloid cells, however aberrant MPO expression has been found to occur in non-myeloid cells in some disease states. The functional -463GA promoter polymorphism alters MPO expression levels. The -463G is within an SP1 binding site and is associated with higher gene expression. The G allele is most frequent with ~62% of European populations being GG homozygotes. The GA polymorphism has been associated with risk or survival in a variety of cancers including lung and breast cancer. In this study we determined the frequency of the -463G/A polymorphism in 230 ovarian cancer patients, 75 patients with borderline ovarian tumors, and 299 healthy controls. The GG genotype was found to be overrepresented in patients with early stage ovarian cancer (83.3% GG, p = 0.008) as compared to healthy controls (62% GG), suggesting that MPO oxidants may increase risk. Immunohistochemical analysis revealed MPO expression in a subset of columnar ovarian epithelial carcinoma cells in early stage carcinomas.
Insights
The myeloperoxidase (MPO) GG genotype, linked to higher MPO expression, is more common in early-stage ovarian cancer patients, suggesting MPO
Area of Science:
- Biochemistry
- Genetics
- Oncology
Background:
- Myeloperoxidase (MPO) is an enzyme typically found in myeloid cells.
- Aberrant MPO expression occurs in non-myeloid cells in certain diseases.
- The MPO -463G/A promoter polymorphism influences MPO gene expression levels.
Purpose of the Study:
- To investigate the frequency of the MPO -463G/A polymorphism in ovarian cancer.
- To explore the association between MPO genotype and early-stage ovarian cancer risk.
- To examine MPO expression in ovarian epithelial carcinoma cells.
Main Methods:
- Genotyping of the MPO -463G/A polymorphism in 230 ovarian cancer patients, 75 borderline ovarian tumor patients, and 299 healthy controls.
- Statistical analysis to compare genotype frequencies between groups.
- Immunohistochemical analysis of MPO expression in ovarian carcinoma tissues.
Main Results:
- The GG genotype was significantly overrepresented in early-stage ovarian cancer patients (83.3%) compared to healthy controls (62%, p=0.008).
- MPO expression was detected in a subset of ovarian epithelial carcinoma cells in early-stage cases.
- The frequency of the -463G/A polymorphism was determined in the study cohorts.
Conclusions:
- The MPO -463 GG genotype may be associated with an increased risk of early-stage ovarian cancer.
- Aberrant MPO expression in ovarian epithelial cells could play a role in ovarian cancer development.
- Further research is warranted to elucidate the role of MPO in ovarian carcinogenesis.
